GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY) » Definitions » EPS without NRI

CLVLY (Clinuvel Pharmaceuticals) EPS without NRI : $0.47 (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals EPS without NRI?

Clinuvel Pharmaceuticals's earnings per share without non-recurring items for the six months ended in Jun. 2024 was $0.32. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was $0.47.

During the past 12 months, Clinuvel Pharmaceuticals's average earnings per share (NRI) Growth Rate was 18.10% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 13.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 14.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Clinuvel Pharmaceuticals's EPS without NRI or its related term are showing as below:

CLVLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -120.6   Med: 13   Max: 32.1
Current: 13

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 13.00% per year.

CLVLY's 3-Year EPS without NRI Growth Rate is ranked better than
60.86% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs CLVLY: 13.00

Clinuvel Pharmaceuticals's EPS (Diluted) for the six months ended in Jun. 2024 was $0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.47.

Clinuvel Pharmaceuticals's EPS (Basic) for the six months ended in Jun. 2024 was $0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.48.


Clinuvel Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Clinuvel Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals EPS without NRI Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.37 0.28 0.40 0.46

Clinuvel Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.16 0.24 0.14 0.32

Competitive Comparison of Clinuvel Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's PE Ratio without NRI falls into.



Clinuvel Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals  (OTCPK:CLVLY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Clinuvel Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

From GuruFocus

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

CLINUVEL Launches CYAC�LLE, Next Generation Solar Care

By sperokesalga sperokesalga 03-01-2023

PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

By Marketwired Marketwired 07-13-2020

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020